Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/20/2024 | $220.00 → $255.00 | Neutral → Buy | BofA Securities |
| 5/8/2024 | $265.00 → $225.00 | Buy → Neutral | BofA Securities |
| 4/19/2024 | $285.00 | Outperform | RBC Capital Mkts |
| 3/19/2024 | $250.00 | Overweight | Morgan Stanley |
| 2/6/2024 | $278.00 | Overweight | KeyBanc Capital Markets |
| 1/19/2024 | $245.00 | Buy | Jefferies |
| 1/2/2024 | $210.00 | Buy → Hold | Stifel |
| 12/13/2023 | $245.00 → $187.00 | Overweight → Equal Weight | Wells Fargo |
BofA Securities upgraded Inspire Medical Systems from Neutral to Buy and set a new price target of $255.00 from $220.00 previously
BofA Securities downgraded Inspire Medical Systems from Buy to Neutral and set a new price target of $225.00 from $265.00 previously
RBC Capital Mkts initiated coverage of Inspire Medical Systems with a rating of Outperform and set a new price target of $285.00
SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)
SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)
SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)
MINNEAPOLIS, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter and year ended December 31, 2024. Recent Business Highlights and Full Year 2025 Guidance Generated revenue of $239.7 million for the fourth quarter of 2024, a 25% increase over the same quarter last year, and revenue of $802.8 million for full year 2024, a 28% increase over full year 2023Achieved gross margin of 85.0% for the fourth quarter of 2024Repo
MINNEAPOLIS, Minn, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) ("Inspire", or the "Company"), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced certain preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024, and provided its initial full year 2025 revenue guidance. Preliminary, Unaudited Fourth Quarter and Full Year 2024 Revenue and Recent Business Highlights Revenue for the fourth quarter of 2024 is anticipated to be in the range of $239.5 million to $239.7 million, an approximately 25% inc
MINNEAPOLIS, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire) will release financial results for the fourth quarter and fiscal 2024 after the close of trading on Monday, February 10. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q4 2024 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, p
4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)
For Immediate Release: March 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA completed its second pre-market consultation for a human food made from cultured animal cells. The firm will use animal cell culture technology to take living cells from chickens and grow the cells in a controlled environment to make the cultured
144 - Inspire Medical Systems, Inc. (0001609550) (Subject)
SCHEDULE 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)
10-K - Inspire Medical Systems, Inc. (0001609550) (Filer)
Presidio Medical, Inc., a clinical stage company developing a transformational neuromodulation platform, is pleased to announce Richard J. Buchholz will join its Board of Directors. Rick is the Chief Financial Officer of Inspire Medical Systems, Inc. (NYSE:INSP), where he has played a pivotal role in driving strategic financial and operational growth for the global leader in the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. "We are excited that Rick is joining the Board of Directors of Presidio Medical at this critical time in our company's journey. His leadership and financial acumen will be instrumental in advanc
NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from
MINNEAPOLIS, July 22, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today the addition of Melissa J. Mann as Chief People Officer, effective July 22, 2024. "We are very excited to welcome Melissa to the Inspire team," said Tim Herbert, Chairman and CEO of Inspire. "In this role, Melissa will be able to leverage her vast experience in human capital management as we continue to grow and scale our organization. Melissa is replacing Steven L. Jandrich, Vice President, Human Resources, who
MINNEAPOLIS, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter and year ended December 31, 2024. Recent Business Highlights and Full Year 2025 Guidance Generated revenue of $239.7 million for the fourth quarter of 2024, a 25% increase over the same quarter last year, and revenue of $802.8 million for full year 2024, a 28% increase over full year 2023Achieved gross margin of 85.0% for the fourth quarter of 2024Repo
MINNEAPOLIS, Minn, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) ("Inspire", or the "Company"), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced certain preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024, and provided its initial full year 2025 revenue guidance. Preliminary, Unaudited Fourth Quarter and Full Year 2024 Revenue and Recent Business Highlights Revenue for the fourth quarter of 2024 is anticipated to be in the range of $239.5 million to $239.7 million, an approximately 25% inc
MINNEAPOLIS, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire) will release financial results for the fourth quarter and fiscal 2024 after the close of trading on Monday, February 10. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q4 2024 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, p
4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)
4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)
4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)